cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bluebird Bio Inc
30 own
36 watching
Current Price
$6.65
$0.02
(0.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
551.15M
52-Week High
52-Week High
8.58
52-Week Low
52-Week Low
2.865
Average Volume
Average Volume
3.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization551.15M
icon52-Week High8.58
icon52-Week Low2.865
iconAverage Volume3.01M
iconDividend Yield--
iconP/E Ratio--
What does the Bluebird Bio Inc do?
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The company's lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Bluebird Bio Inc make?
News & Events about Bluebird Bio Inc.
Ticker Report
8days ago
bluebird bio, Inc. (NASDAQ:BLUE Get Rating) has earned a consensus rating of Hold from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy ...
Business Wire
16days ago
bluebird bio, Inc. (Nasdaq: BLUE) (bluebird) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a...
Business Wire
26days ago
bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at...
Business Wire
29days ago
bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million. bluebird bio was granted two PRVs upon the US Food and Drug Administration (FDA...
Business Wire
1month ago
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing, collaborations and mergers and acquisitions, financial...
Frequently Asked Questions
Frequently Asked Questions
What is Bluebird Bio Inc share price today?
plus_minus_icon
Can Indians buy Bluebird Bio Inc shares?
plus_minus_icon
How can I buy Bluebird Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Bluebird Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bluebird Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Bluebird Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Bluebird Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bluebird Bio Inc?
plus_minus_icon
What percentage is Bluebird Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bluebird Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.65
$0.02
(0.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Mesoblast
Mesoblast
$3.66
$0.02 (0.55 %)
Coherus BioSciences Inc
Coherus BioSciences Inc
$8.49
$-0.47 (-5.25 %)
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
$1.91
$0.12 (6.70 %)
NanoString Technologies Inc
NanoString Technologies Inc
$12.08
$-0.49 (-3.90 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Mesoblast
Mesoblast
$3.66
$0.02 (0.55 %)
Coherus BioSciences Inc
Coherus BioSciences Inc
$8.49
$-0.47 (-5.25 %)
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
$1.91
$0.12 (6.70 %)
NanoString Technologies Inc
NanoString Technologies Inc
$12.08
$-0.49 (-3.90 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00